Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
763 Views
InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside
InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...
686 Views
InnoCare (诺诚健华) Pre-IPO: PHIP and Valuation Update
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
708 Views
InnoCare (诺诚健华) Pre-IPO: Thoughts on Valuation
InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...
701 Views
Ascentage Pharma (亚盛医药) IPO: Some Issues with Banker Forecasts
Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...
1.2k Views